[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

BR112017008280A2 - método para o tratamento de um paciente - Google Patents

método para o tratamento de um paciente

Info

Publication number
BR112017008280A2
BR112017008280A2 BR112017008280-2A BR112017008280A BR112017008280A2 BR 112017008280 A2 BR112017008280 A2 BR 112017008280A2 BR 112017008280 A BR112017008280 A BR 112017008280A BR 112017008280 A2 BR112017008280 A2 BR 112017008280A2
Authority
BR
Brazil
Prior art keywords
patient
treating
cell carcinoma
hpv
cancer
Prior art date
Application number
BR112017008280-2A
Other languages
English (en)
Inventor
Ioannides Tim
Original Assignee
Hpvvax, Llc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hpvvax, Llc. filed Critical Hpvvax, Llc.
Publication of BR112017008280A2 publication Critical patent/BR112017008280A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/12—Keratolytics, e.g. wart or anti-corn preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20071—Demonstrated in vivo effect

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Communicable Diseases (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

um método para tratar ou reduzir a incidência de recorrência de câncer, tumores benignos ou lesões associadas a hpv, incluindo câncer da pele, e particularmente carcinoma de células escamosas (cce) e carcinoma basocelular (cbc), administrando uma ou mais doses de hpv recombinante a um paciente
BR112017008280-2A 2014-10-24 2015-10-23 método para o tratamento de um paciente BR112017008280A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462068332P 2014-10-24 2014-10-24
US62/068,332 2014-10-24
PCT/US2015/057150 WO2016065281A1 (en) 2014-10-24 2015-10-23 Cancer and skin lesion treatment

Publications (1)

Publication Number Publication Date
BR112017008280A2 true BR112017008280A2 (pt) 2018-01-02

Family

ID=55761638

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112017008280-2A BR112017008280A2 (pt) 2014-10-24 2015-10-23 método para o tratamento de um paciente

Country Status (15)

Country Link
US (1) US10238729B2 (pt)
EP (1) EP3209676A4 (pt)
JP (1) JP6663438B2 (pt)
KR (1) KR102285401B1 (pt)
CN (1) CN107001430A (pt)
AU (1) AU2015335652B2 (pt)
BR (1) BR112017008280A2 (pt)
CA (1) CA2965498A1 (pt)
CL (1) CL2017001008A1 (pt)
IL (1) IL251825B2 (pt)
MX (1) MX2017005418A (pt)
MY (1) MY195018A (pt)
PH (1) PH12017500754A1 (pt)
SG (1) SG11201703262UA (pt)
WO (1) WO2016065281A1 (pt)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2018010338A (es) * 2016-02-27 2018-11-09 Hpvvax Llc Metodo y composicion para tratamiento del cancer o una lesion de la piel utilizando una vacuna.

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2284559T3 (es) * 2001-03-23 2007-11-16 Deutsches Krebsforschungszentrum Stiftung Des Offentlichen Rechts Genes y proteinas e6 y e7 modificados del vph utiles como vacuna.
GB0110431D0 (en) * 2001-04-27 2001-06-20 Glaxosmithkline Biolog Sa Novel compounds
US20060222656A1 (en) 2005-04-01 2006-10-05 University Of Maryland, Baltimore MAGE-A3/HPV 16 peptide vaccines for head and neck cancer
GB0206359D0 (en) * 2002-03-18 2002-05-01 Glaxosmithkline Biolog Sa Viral antigens
GB0206360D0 (en) * 2002-03-18 2002-05-01 Glaxosmithkline Biolog Sa Viral antigens
GB0222953D0 (en) * 2002-10-03 2002-11-13 Glaxo Group Ltd Novel Compounds
EA200701633A1 (ru) 2002-12-20 2007-12-28 Глаксосмитклайн Байолоджикалс С.А. Вакцина на основе вирусоподобных частиц вируса папилломы человека 16 и вируса папилломы человека 18 l1
AR049354A1 (es) * 2004-06-16 2006-07-19 Glaxosmithkline Biolog Sa VACUNACONTRA PAPILOMAVIRUS HUMANO(VPH) Y PROCEDIMIENTO DE PREPARACIoN
GB0417430D0 (en) 2004-08-05 2004-09-08 Uc3 A novel HPV vaccine comprising peptides from host cell proteins
US8399610B2 (en) 2004-08-05 2013-03-19 University College Cardiff Consultants Limited HPV vaccine comprising peptides from host cell proteins
WO2008112125A1 (en) * 2007-03-09 2008-09-18 Merck & Co., Inc. Papillomavirus vaccine compositions
CN101530612A (zh) * 2008-03-10 2009-09-16 北京康乐卫士生物技术有限公司 16型重组人乳头瘤病毒疫苗
CN101530614A (zh) * 2008-03-10 2009-09-16 北京康乐卫士生物技术有限公司 五价重组人乳头瘤病毒疫苗
US20110110979A1 (en) 2008-04-16 2011-05-12 Universite De Lausanne Method and vaccine for optimizing the specific immune responses
EP2416798B1 (en) * 2009-04-10 2017-09-20 The Johns Hopkins University Papillomavirus-like particles (vlp) as broad spectrum human papillomavirus (hpv) vaccines
ES2683352T3 (es) * 2009-04-13 2018-09-26 Inserm - Institut National De La Santé Et De La Recherche Médicale Partículas de HPV y usos de las mismas
CN101890160B (zh) * 2009-04-28 2014-06-18 北京康乐卫士生物技术有限公司 多价重组人乳头瘤病毒疫苗及其应用
US9566323B2 (en) 2009-06-19 2017-02-14 Eyegene Inc. Vaccine for cervical cancer
CA2768172A1 (en) * 2009-06-25 2010-12-29 Glaxosmithkline Biologicals S.A. Novel compositions
AR074485A1 (es) 2009-12-04 2011-01-19 Consejo Nac Invest Cient Tec Vacuna contra lesiones neoplasicas o cancerosas causadas por el virus del papiloma humano (vph), procedimientos, usos y metodos
WO2012170384A1 (en) * 2011-06-06 2012-12-13 Chevron Phillips Chemical Company Lp Use of metallocene compounds for cancer treatment
US20130064849A1 (en) * 2011-07-14 2013-03-14 The Board Of Regents Of The University Of Texas Methods to treat and prevent cardiovascular disease using human papillomavirus vaccines
WO2013139744A1 (en) * 2012-03-18 2013-09-26 Glaxosmithkline Biologicals S.A. Method of vaccination against human papillomavirus
WO2013149017A1 (en) * 2012-03-28 2013-10-03 Kansas State University Research Foundation Vaccine adjuvant
US20140275082A1 (en) * 2013-03-14 2014-09-18 Abbvie Inc. Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
US9974849B2 (en) 2013-10-13 2018-05-22 Bioventures, Llc Human Papilloma virus therapeutic vaccine

Also Published As

Publication number Publication date
KR20170072279A (ko) 2017-06-26
PH12017500754A1 (en) 2017-10-30
IL251825B2 (en) 2023-09-01
JP2017531699A (ja) 2017-10-26
AU2015335652B2 (en) 2020-07-02
US10238729B2 (en) 2019-03-26
CA2965498A1 (en) 2016-04-28
JP6663438B2 (ja) 2020-03-11
SG11201703262UA (en) 2017-05-30
CL2017001008A1 (es) 2017-11-24
EP3209676A4 (en) 2018-03-28
CN107001430A (zh) 2017-08-01
KR102285401B1 (ko) 2021-08-02
MY195018A (en) 2023-01-03
EP3209676A1 (en) 2017-08-30
WO2016065281A1 (en) 2016-04-28
MX2017005418A (es) 2017-11-30
IL251825B1 (en) 2023-05-01
AU2015335652A1 (en) 2017-05-25
IL251825A0 (en) 2017-06-29
US20160114023A1 (en) 2016-04-28

Similar Documents

Publication Publication Date Title
NZ732211A (en) Combination immunotherapy approach for treatment of cancer
CL2018000706A1 (es) Derivados de pirazolopirimidina como inhibidores btk para el tratamiento del cancer.
CO2017004932A2 (es) Métodos para seleccionar una línea de células t y donador de la misma para terapia celular adoptiva
NZ749218A (en) Androgen receptor modulator and uses thereof
NZ746338A (en) Use of alphavirus and zap inhibitor in the preparation of an antitumor drug, and antitumor drugs comprising the same
MX2021006734A (es) Metodo para tratar el cancer.
MA40458A (fr) Méthodes de traitement du cancer du col de l'utérus
TN2017000554A1 (en) Novel combination for use in the treatment of cancer
TR201901422T4 (tr) Tümörlerin tedavisinde kullanım için korteksolon 17A,21-diesterleri.
BR112017023517A2 (pt) anticorpo anti-cd20 para tratamento do câncer, composição farmacêutica, método de tratamento de um paciente que sofre de câncer e uso de um anticorpo anti-cd20
PH12018500254A1 (en) Combinations of an ox40 antibody and a tlr4 modulator and uses thereof
AU2016206832A8 (en) Non-invasive systems and methods for treatment of a host carrying a virus with photoactivatable drugs
BR112017021700A2 (pt) composições terapêuticas e métodos de uso para o tratamento do câncer
MX2019005450A (es) Composiciones y metodos farmaceuticos.
JO3541B1 (ar) علاجات طبية قائمة على اناموريلين
MX2017010341A (es) Terapia para cancer con un parvovirus combinado con bevacizumab.
MY181685A (en) Methods and compositions comprising ursolic acid and/or resveratrol for treating obesity, diabetes, or cancer
EP3597207A4 (en) COMPOSITION TYPE OF TRADITIONAL CHINESE MEDICINE FOR TREATMENT OF TUMORS, METHOD OF MANUFACTURING THEREOF AND USES THEREOF
MX370519B (es) Sulfonamidas con sustitucion biarilo y su uso.
WO2019103449A3 (ko) 항암바이러스의 간동맥 투여를 이용한 간암 치료방법
CL2018002438A1 (es) Método y composición para el tratamiento del cáncer o una lesión de la piel utilizando una vacuna.
BR112015025697A2 (pt) cepa do vírus vaccinia mutante, uso da cepa do vírus vaccinia mutante, método para a produção de um produto de gene recombinante e produto de gene recombinante
BR112017008280A2 (pt) método para o tratamento de um paciente
MX2017013666A (es) Terapia de combinacion de agente anti-fuctactico y agente de inmunoterapia y composiciones para el tratamiento de cancer.
WO2018148180A3 (en) Materials and methods for identifying and treating cancer patients

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B12B Appeal against refusal [chapter 12.2 patent gazette]